Inmed Pharmaceuticals Inc. current report, 11 February 2022

Vollständiges Dokument

Business Context and Reporting Period

This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on February 23, 2022, covering events that occurred on February 11, 2022. The company is incorporated in British Columbia and its common shares trade on The Nasdaq Stock Market LLC under the symbol "INM".

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.

Material Changes

  • Director Resignation: Catherine Sazdanoff resigned from the Board of Directors and all associated committees (Compensation, Nominating & Governance, and Audit) effective February 11, 2022, citing personal reasons.
  • Director Appointment: Janet Grove was appointed to the Board to fill the vacancy created by Ms. Sazdanoff's resignation, effective February 11, 2022. Her term expires at the 2022 Annual General Meeting.
  • Committee Assignments: Ms. Grove will serve on the Compensation Committee and the Nominating & Governance Committee.

Compensation and Governance Details

Ms. Grove's compensation package includes:

  • An annual retainer of $35,000.
  • Up to an additional $15,000 per year for committee participation (assuming a minimum of two committee memberships).
  • Stock options to purchase 14,000 common shares, consistent with the standard grant for new directors.
  • Execution of the Company's standard director indemnification agreement.

The filing states there are no family relationships between Ms. Grove and other directors or executive officers, and no special arrangements influenced her selection.

Investor Verification Checklist

  • Verify the effective date of Ms. Sazdanoff's resignation and Ms. Grove's appointment (February 11, 2022).
  • Confirm the specific committees Ms. Grove joined (Compensation and Nominating & Governance).
  • Review the stock option grant details (14,000 shares) for new directors.
  • Note that the filing references a separate press release and Form 8-K filed on February 14, 2022, for further details.